Success Metrics

Clinical Success Rate
75.0%

Based on 15 completed trials

Completion Rate
75%(15/20)
Active Trials
2(7%)
Results Posted
40%(6 trials)
Terminated
5(17%)

Phase Distribution

Ph early_phase_1
2
7%
Ph phase_1
4
13%
Ph not_applicable
10
33%
Ph phase_2
4
13%
Ph phase_4
3
10%
Ph phase_3
3
10%

Phase Distribution

6

Early Stage

4

Mid Stage

6

Late Stage

Phase Distribution26 total trials
Early Phase 1First-in-human
2(7.7%)
Phase 1Safety & dosage
4(15.4%)
Phase 2Efficacy & side effects
4(15.4%)
Phase 3Large-scale testing
3(11.5%)
Phase 4Post-market surveillance
3(11.5%)
N/ANon-phased studies
10(38.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

60.0%

15 of 25 finished

Non-Completion Rate

40.0%

10 ended early

Currently Active

2

trials recruiting

Total Trials

30

all time

Status Distribution
Active(2)
Completed(15)
Terminated(10)
Other(3)

Detailed Status

Completed15
Terminated5
Withdrawn5
unknown3
Recruiting2

Development Timeline

Analytics

Development Status

Total Trials
30
Active
2
Success Rate
75.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 12 (7.7%)
Phase 14 (15.4%)
Phase 24 (15.4%)
Phase 33 (11.5%)
Phase 43 (11.5%)
N/A10 (38.5%)

Trials by Status

recruiting27%
completed1550%
terminated517%
unknown310%
withdrawn517%

Recent Activity

Clinical Trials (30)

Showing 20 of 30 trialsScroll for more
NCT05179200Not Applicable

The Effect of Plasma Donation Frequency on Donor Health

Completed
NCT07087860Phase 2

Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers

Recruiting
NCT03763643Early Phase 1

PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant

Completed
NCT06597656Phase 1

A Gene Transfer Therapy to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Therapeutic Plasma Exchange (Plasmapheresis) in Participants With Duchenne Muscular Dystrophy (DMD) and Pre-existing Antibodies to AAVrh74

Terminated
NCT01350232Not Applicable

Treatment of Sickle Cell Anemia With Stem Cell Transplant

Terminated
NCT03887741Phase 1

Plasmapheresis Versus Plasma Infusion from Young APOE3 Homozygotes Into MCI APOE4 Homozygotes to Slow Disease Progression

Completed
NCT05562960Not Applicable

Plasmapheresis in Amyotrophic Lateral Sclerosis With Autoantibody Against NRIP

Recruiting
NCT04776850Early Phase 1

Pre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe Hemoglobinopathies

Withdrawn
NCT05004220

Effects of Plasmapheresis on Aging Biomarkers

Completed
NCT05543590Not Applicable

Effect of Plasmapheresis on Clinical Improvement and Biological Parameters of Patients With Long-haul COVID

Withdrawn
NCT05815615Not Applicable

Plasmapheresis: a Multi-modal Approach

Completed
NCT04927598

Predictors and Prognostic Factors of Gullian Barrie Syndrome Outcome

Completed
NCT01214317Not Applicable

Study of Induction Therapy With Mitoxantrone and Plasmapheresis to Treat Aggressive Multiple Sclerosis

Completed
NCT02522572Phase 1

Quantitating the Impact of Plerixafor

Unknown
NCT03965559

The Efficacy of Plasmapheresis and Double Filtration Plasmapheresis (DFPP) in Kidney Transplant

Completed
NCT03115697Not Applicable

High Volume Plasmapheresis for Refractory Hepatic Encephalopathy in Liver Intensive Care Unit.

Withdrawn
NCT02671682Not Applicable

Immunoadsorption vs. Plasmapheresis in the Escalation Therapy of Relapse in Multiple Sclerosis

Completed
NCT02500251Phase 1

Belimumab Impacting Transplant Eligibility

Completed
NCT03501680Phase 4

Intensive Insulin for Severe/Moderate Hypertriglyceridemia Pancreatitis.

Unknown
NCT00275509Phase 3

Induction Therapy Study in Live Donor Kidney Transplant Recipients With a Positive Crossmatch

Completed

Drug Details

Intervention Type
PROCEDURE
Total Trials
30